All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
Myeloproliferative neoplasms (MPN) are very rare in young patients compared with adults. Not surprisingly, diagnostic criteria, risk classification, or treatment guidelines in polycythemia vera (PV) and essential thrombocythemia (ET) focus mainly on adult patients.
Hydroxyurea is commonly used in children for the treatment of PV/ET, however, there are concerns over its impact on leukemic transformation and fertility, and therefore the advice is to use it cautiously. On the other hand, there is years of experience with interferon treatment in adult patients, which is associated with hematologic and molecular responses. With the development of pegylated forms, interferon also shows improved tolerability in adult patients with PV/ET.
Based on a potential benefit of pegylated interferon (Peg) and the lack of knowledge in children with PV/ ET, Nicole Kucine et al. evaluated the outcomes in young patients (aged < 21 years) with PV/ET who received Peg, and the results were recently published in Pediatric Blood & Cancer.1
This is a retrospective study, where records were reviewed of patients younger than 21 years who were diagnosed with PV/ET and treated with Peg at any time following diagnosis.
Characteristics of 13 patients (ET, n = 6; PV, n = 7) are summarized in Table 1. Splenomegaly (n = 6) and splanchnic vein thrombosis (n = 1) were reported at the time of diagnosis.
Table 1. Patient characteristics (N = 13)*
Characteristic |
ET |
PV |
---|---|---|
Median age at diagnosis, years (IQR) |
12. 5 (10–14) |
10 (2–16) |
Median age at the start of Peg, years (IQR) |
14 (11–15) |
10 (9–19) |
Male sex, n |
2 |
3 |
Mutational status, n |
|
|
Extreme thrombocytosis with platelet count > 1000 × 109/L |
5 |
4 |
ET, essential thrombocythemia; IQR, interquartile range; Peg, pegylated interferon; PV, polycythemia vera. |
Of the 13 patients, seven were treated with hydroxyurea before initiating Peg and three patients received hydroxyurea combined with Peg.
Cytoreductive therapy with hydroxyurea was initiated to treat acquired von Willebrand disease, extreme thrombocytosis, severe iron deficiency, and systemic symptoms.
Reasons for initiating Peg treatment were related to concerns for hydroxyurea-associated malignancies, the impact of hydroxyurea on fertility, possible disease-modifying effects of Peg, and side effects related to hydroxyurea.
Patient-reported side effects included dizziness, malaise, and injection site reactions not requiring treatment discontinuation. Therefore, treatment continuation rate was high at 62%.
However, five patients discontinued Peg treatment due to:
The time of treatment initiation in young patients with PV/ET is still far from clear, and there is a lack of established criteria, such as laboratory values, symptoms, or thrombotic events, to inform the decision-making process. The authors highlight the need for identifying appropriate therapeutic targets in young patients.
In this retrospective case series of 13 pediatric patients, Peg was relatively well tolerated, showed a low discontinuation rate, and was associated with platelet reduction in cases of extreme thrombocytosis. None of the patients experienced transformation of their disease into a fibrotic phase, which has been reported in up to 2% of young patients with PV/ET.
While further evaluation of Peg is deemed necessary in larger trials with young patients, the authors advocate to include interferon as a first-line treatment option in young patients with PV and ET.
The World Health Organization (WHO) recently reviewed its diagnostic criteria to include proposed criteria for children with MPN, and Table 2 provides a comparison of diagnostic criteria for adults and pediatric patients.2
Table 2. WHO diagnostic criteria for adult and pediatric patients with polycythemia vera/essential thrombocythemia*
Polycythemia vera |
|||
---|---|---|---|
Current WHO criteria |
Proposed pediatric criteria |
||
Major criteria |
Major criteria |
||
1 Hb > 165 g/L in men, > 160 g/L in women |
1 |
Hb or HCT > 97.5th percentile for age/gender |
|
2 |
BM biopsy with hypercellularity for age, trilineage growth, and pleiomorphic megakaryocytic proliferation with mature megakaryocytes |
2 |
BM biopsy that is hypercellular or normocellular for age, trilineage growth, and pleiomorphic megakaryocytic proliferation with mature megakaryocytes |
3 |
Presence of JAK2 V617F or JAK2 exon 12 mutation |
3 |
Presence of JAK2 V617F or JAK2 exon 12 mutation |
Minor criteria |
Minor criteria |
||
1 |
Subnormal erythropoietin |
1 |
Subnormal erythropoietin |
Essential thrombocythemia |
|||
Current WHO criteria |
Proposed pediatric criteria |
||
Major criteria |
Major criteria |
||
1 |
Platelet count ≥ 450 × 109/L |
1 |
Platelet count ≥ 450 × 109/L for at least 3 months |
2 |
BM biopsy showing primarily proliferation of megakaryocytes with increased, mature, hyperlobulated megakaryocytes, with no significant increase in granulopoiesis or erythropoiesis, and rarely minor increase in reticulin fibrosis |
2 |
BM biopsy showing primarily proliferation of megakaryocytes with increased, mature, hyperlobulated megakaryocytes, with no significant increase in granulopoiesis or erythropoiesis, and rarely minor increase in reticulin fibrosis |
3 |
Not meeting WHO criteria for BCR-ABL1+ CML or other MPN |
3 |
Not meeting WHO criteria for BCR-ABL1+ CML or other MPN |
4 |
JAK2, MPL, or CALR mutation |
4 |
Presence of a clonal marker including JAK2, MPL, or CALR mutation |
Minor criteria |
|||
1 |
Presence of a clonal marker or absence of a reactive thrombocytosis |
||
BM, bone marrow; CML, chronic myeloid leukemia; Hb, hemoglobin; HCT, hematocrit; MPN, myeloproliferative neoplasm; RBC, red blood cell; WHO, World Health Organization. |
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox